[Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity].
Foa
C
C
Bondiau
P Y
PY
Largillier
R
R
Milano
G
G
Magné
N
N
D000008:Abdominal Neoplasms / Q000188:drug therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D042943:Dihydrouracil Dehydrogenase (NADP); D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007264:Inguinal Canal; D007680:Kidney Neoplasms / Q000473:pathology*; D008214:Lymphocytes / Q000201:enzymology; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010088:Oxidoreductases / Q000172:deficiency*; D014846:Vulvar Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery
D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP); D002945:Cisplatin; D005472:Fluorouracil